Pharmacyclics, Inc. (NASDAQ:PCYC) announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) …
In a research report issued today, Piper Jaffray analyst Joshua Schimmer reiterated a Neutral rating on Pharmacyclics, Inc. (NASDAQ:PCYC) with a price target of …
